Short answer
Praxis Precision Medicines, Inc. (PRAX) filed an 8-K current report with the SEC on June 29, 2026 reporting Item 8.01 (Other Events). FDA PDUFA action date delayed three months, from September 27 to December 27, 2026.
Praxis Precision Medicines, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA PDUFA action date delayed three months, from September 27 to December 27, 2026
- Relutrigine NDA review covers SCN2A and SCN8A developmental and epileptic encephalopathies
- Delay triggered by additional sensitivity analyses classified as a major amendment
- No new clinical studies requested and no FDA safety or manufacturing concerns cited
- Regulatory uncertainty extends, postponing potential approval and commercial launch timing
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Praxis Precision Medicines, Inc. 8-K filings
Get the next PRAX 8-K as it lands
Follow PRAX for push alerts, or ask the research agent what this filing means.